ArticleCardiovascular diabetology2025
Correlation between atherogenic index of plasma and cardiovascular disease risk across Cardiovascular-kidney-metabolic syndrome stages 0-3: a nationwide prospective cohort study.
Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Article
- Depression and risk of incident heart diseases among older adults at CKM stages 0-3: evidence from the China Health and Retirement Longitudinal Study.Annals of medicine · 2026Article
- Antecedent, landmark, and two-visit cumulative triglyceride-glucose index and non-traditional lipid measures in relation to incident cardiovascular disease in adults with cardiovascular-kidney-metabolic syndrome (CKM) stages 0-3: a nationwide prospective cohort study.Cardiovascular diabetology · 2026Article
- Association between the atherogenic index of plasma and prognosis in kidney transplant recipients: a retrospective cohort study.International urology and nephrology · 2026Article
- Association of the cardiometabolic index and depressive symptoms with cardiovascular disease in cardiovascular-kidney-metabolic syndrome stages 0-3: A prospective cohort study.Scientific reports · 2026Article
- Joint association of Insulin resistance and frailty index with incident ASCVD and MACE in individuals with cardiovascular-kidney-metabolic syndrome stages 0-3: a multi-cohort study.Cardiovascular diabetology · 2026Observational
- Insulin resistance surrogate indices and incident cardiovascular disease across cardiovascular-kidney-metabolic stages 0-3: a prospective cohort study.Cardiovascular diabetology · 2026Article
- Association between insulin resistance surrogate markers and cardiovascular disease risk in individuals with subclinical metabolic disorders: a prospective cohort study based on baseline levels, cumulative exposure, and longitudinal trajectories.Cardiovascular diabetology · 2026Article
- Associations of the atherogenic index of plasma and its modified indices with the incidence and progression of cardiometabolic multimorbidity in individuals with cardiovascular-kidney-metabolic syndrome stages 0-3: a prospective cohort study.Cardiovascular diabetology · 2026Article
- Integrating inflammation, insulin resistance, and visceral adiposity: the C-reactive protein-triglyceride-glucose-Chinese visceral adiposity (CTI-CVAI) index is associated with cardiovascular disease risk across CKM stages 0-3 in a nationwide prospective cohort.Cardiovascular diabetology · 2026Article
- Association between the atherogenic index of plasma trajectory and risk of cardiovascular diseases among hypertensive patients: a prospective cohort study.Cardiovascular diabetology. Endocrinology reports · 2026Article
- Joint association of atherogenic index of plasma and estimated glucose disposal rate with new-onset cardiovascular disease risk in individuals with cardiovascular-kidney-metabolic syndrome stages 0-3: a 9-year nationwide prospective cohort study.Cardiovascular diabetology · 2026Article
- Cardiovascular-kidney-metabolic syndrome: a comprehensive review of pathophysiology, epidemiology, diagnosis, and management.Cardiovascular diabetology · 2026Review
- Emerging multidimensional biomarker system for cardiovascular-kidney-metabolic syndrome: from multi-omics integration to clinical artificial intelligence.Cardiovascular diabetology · 2026Review
- Remnant Cholesterol Inflammatory Index and Its Association With All-Cause Mortality Among General Population and Individuals With Cardiovascular-Kidney-Metabolic Syndrome Stages 0-3: Evidence From Two Nationwide Studies.Clinical cardiology · 2026Article
- Prognostic effect of estimated glucose disposal rate on all-cause and cardiovascular mortality among individuals cardiovascular-kidney-metabolic syndrome.Diabetology & metabolic syndrome · 2026Article
- Article
- Association of cardiometabolic index with incident cardiovascular disease in middle-aged and older adults with cardiovascular-kidney-metabolic syndrome stages 0-3: evidence from CHARLS (2011-2020).Scientific reports · 2026Article
- Associations between lipid-derived indices and cardiovascular-kidney-metabolic syndrome progression among Chinese middle-aged and elderly adults: a longitudinal study.Frontiers in nutrition · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe Cardiovascular-kidney-metabolic (CKM) syndrome, a concept recently proposed by the American Heart Association (AHA), highlights the intricate connection between metabolic, renal, and cardiovascular illnesses. Furthermore, the Atherogenic Index of Plasma (AIP), a useful biomarker for evaluating the risk of Cardiovascular Diseases (CVDs), has been associated with the risk of Adverse Cardiovascular Events (ACEs). Nonetheless, its precise function in populations in CKM syndrome Stages 0-3 remains unknown.
methodsThis prospective study analyzed the data of 7,708 eligible participants (aged ≥ 45 years) from the Chinese Longitudinal Research of Ageing (CHARLS), particularly the 2011-2012 baseline survey (Wave 1). The primary exposure variable was AIP-a natural logarithm of the ratio of Triglycerides (TGs) to High-Density Lipoprotein Cholesterol (HDL-C). On the other hand, the primary endpoint was CVD incidence, which was determined based on self-reported past diagnoses. The relationship between AIP and CVD risk in the population in CKM syndrome stages 0-3 was examined using a Cox proportional risk model. Subgroup and mediation analyses were performed to further elucidate the interactions among these factors.
resultsThis study involved 7,708 participants in the CKM syndrome stages 0-3 [Mean age = 58.00 years; Interquartile Range (IQR) = 52.00-65.00 years]. The risk of developing CVD increased significantly with higher AIP levels. Specifically, the risk ratio for each unit increase in AIP was 1.31 (95% CI 1.11-1.55), while the Hazard Ratio (HR) for the group with the highest AIP levels compared to the group with the lowest AIP levels was 1.22 (95% CI 1.08-1.39). Mediation analysis revealed that metabolic syndrome accounted for 12.3% of the association between AIP levels and CVD risk (p = 0.024), highlighting its significance in CVD risk assessment.
conclusionHerein, AIP levels correlated significantly positively with CVD risk in individuals in CKM stages 0-3, with metabolic syndrome as a key mediating factor. These findings suggest that AIP levels could be valuable not only for CVD risk assessment but also for clinical screening.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.